In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of Adc Therapeutics SA (NYSE: ADCT) closed at $3.11 in the last session, down -4.01% from day before closing price of $3.24. In other words, the price has decreased by -$4.01 from its previous closing price. On the day, 0.99 million shares were traded. ADCT stock price reached its highest trading level at $3.24 during the session, while it also had its lowest trading level at $3.03.
Ratios:
We take a closer look at ADCT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.66 and its Current Ratio is at 4.93.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on November 08, 2024, initiated with a Overweight rating and assigned the stock a target price of $6.
On March 28, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $11.Guggenheim initiated its Buy rating on March 28, 2024, with a $11 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 11 ’24 when Redmile Group, LLC bought 100,000 shares for $3.04 per share. The transaction valued at 304,500 led to the insider holds 15,666,731 shares of the business.
Redmile Group, LLC bought 100,000 shares of ADCT for $304,500 on Dec 11 ’24. The 10% Owner now owns 13,145,712 shares after completing the transaction at $3.04 per share. On Dec 04 ’24, another insider, Redmile Group, LLC, who serves as the 10% Owner of the company, sold 25,352 shares for $2.07 each. As a result, the insider received 52,479 and left with 15,566,731 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADCT now has a Market Capitalization of 349871872 and an Enterprise Value of 536080128. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.53. Its current Enterprise Value per Revenue stands at 6.94 whereas that against EBITDA is -4.25.
Stock Price History:
The Beta on a monthly basis for ADCT is 2.01, which has changed by 0.05782318 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, ADCT has reached a high of $3.97, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 2.81%, while the 200-Day Moving Average is calculated to be 41.39%.
Shares Statistics:
According to the various share statistics, ADCT traded on average about 829.36K shares per day over the past 3-months and 766600 shares per day over the past 10 days. A total of 112.50M shares are outstanding, with a floating share count of 88.15M. Insiders hold about 21.65% of the company’s shares, while institutions hold 59.29% stake in the company. Shares short for ADCT as of 1753920000 were 5679129 with a Short Ratio of 6.85, compared to 1751241600 on 4906182. Therefore, it implies a Short% of Shares Outstanding of 5679129 and a Short% of Float of 6.239999999999999.
Earnings Estimates
The dynamic stock of Adc Therapeutics SA (ADCT) is currently being evaluated by a team of 7.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.23 and low estimates of -$0.43.
Analysts are recommending an EPS of between -$1.4 and -$1.73 for the fiscal current year, implying an average EPS of -$1.53. EPS for the following year is -$1.31, with 5.0 analysts recommending between -$0.81 and -$1.97.
Revenue Estimates
According to 6 analysts, the current quarter’s revenue is expected to be $18.51M. It ranges from a high estimate of $19.2M to a low estimate of $17.6M. As of the current estimate, Adc Therapeutics SA’s year-ago sales were $18.46MFor the next quarter, 6 analysts are estimating revenue of $18.56M. There is a high estimate of $19.6M for the next quarter, whereas the lowest estimate is $17.5M.
A total of 5 analysts have provided revenue estimates for ADCT’s current fiscal year. The highest revenue estimate was $80.7M, while the lowest revenue estimate was $77.1M, resulting in an average revenue estimate of $78.73M. In the same quarter a year ago, actual revenue was $70.84MBased on 5 analysts’ estimates, the company’s revenue will be $80.58M in the next fiscal year. The high estimate is $102.3M and the low estimate is $68.6M.
